Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Section Navigation
			
			CDC Home








Reported Tuberculosis in the United States, 2022						Print
																Related Pages
										Return to Main MenuDemographics**On This Page**
			HighlightsOrigin of BirthRace/EthnicityAgeSexData TablesHighlightsDemographic characteristics analysis includes
Origin of Birth
Race/Ethnicity
Age
SexDemographic characteristics of persons diagnosed with TB disease remain similar to previous years.Origin of BirthBecause of the substantially greater risk of exposure to TB outside of the United States, origin of birth is a prominent risk factor for TB in the United States.
TB Cases and Incidence Rates by Origin of Birth, United States, 2022View LargerCloseTB Cases and Incidence Rates by Origin of Birth, United States, 2022Download Image[PNG]
Consistent with previous years, in 2022, the majority of reported TB cases occurred among non-U.S.–born persons (73.8%). The number of TB cases diagnosed among non-U.S.–born persons within the first year after arrival in the United States nearly doubled compared with 2021 and reached the highest level since 2016.
During 2022, the incidence rate (cases per 100,000 persons) was 17.1 times higher among non-U.S.–born persons (13.0) than U.S.-born persons (0.8).
Among non-U.S.–born persons with TB disease during 2022, the most common countries of birth included
Mexico, 18.9%
Philippines, 10.9%
India, 8.8%
Vietnam, 8.2%
China, 6.0%These countries have been the most common countries of birth among non-U.S.–born persons with TB since 2018, and they also represent substantial proportions of the non-U.S.–born population living in the United States. Small but noteworthy increases occurred among persons born in several Central and South American countries (e.g., increase of 41.1% among persons born in El Salvador and 98.4% among persons born in Peru) as well as Afghanistan (an increase of 53.8%), which might reflect changes in migration patterns, including increased arrivals to the United States among persons from other parts of the world.Race/EthnicityPercentage of TB Cases by Race/Ethnicity,* United States, 2022View LargerClosePercentage of TB Cases by Race/Ethnicity,* United States, 2022Download Image[PNG]
Anyone can get TB disease, but some groups have a higher risk for TB than others.
During 2022, persons with TB disease in the United States most commonly identified as:
Non-Hispanic Asian persons (34.3%)
Hispanic or Latino persons (33.9%)
Non-Hispanic Black or African American persons (15.8%)
Non-Hispanic White persons (10.2%)During 2022, TB incidence rates (cases per 100,000 persons) varied by race/ethnicity groups:
TB Incidence Rates by Race/Ethnicity, United States, 2011-2022View LargerCloseTB Incidence Rates by Race/Ethnicity, United States, 2011-2022Download Image[PNG]
Native Hawaiian or Other Pacific Islander persons, 24.4
Asian persons, 14.1
American Indian or Alaska Native persons, 4.6
Hispanic or Latino persons, 4.4
Black or African American persons, 3.1
Persons who identify with more than one race, 1.2
White persons, 0.4AgeTB Incidence Rates by Age Group, United States, 1993–2022View LargerCloseTB Incidence Rates by Age Group, United States, 1993–2022Download Image[PNG]
TB incidence rates were higher among adults than among children. Among persons 5 years and older, the incidence rates increase with age. TB risk increases with age because of a combination of age-related changes in TB exposure, risk of comorbidities, and immune function. During 2022,
Persons aged 5–14 years had the lowest TB incidence rate (0.4).
Persons aged 65 years or older had the highest TB incidence rate (3.9).
Incidence rates were steady or increased during 2022 compared with 2021 for all age groups. However, compared with 2019, TB incidence rates during 2022 remained the same or lower for each age group.SexPercentage of TB Cases by Sex and Age Group, United States, 2022View LargerClosePercentage of TB Cases by Sex and Age Group, United States, 2022Download Image[PNG]
During 2022, male persons accounted for 61.9% of TB cases in the United States, including 62.5% of cases among U.S.-born persons and 61.9% of cases among non-U.S.–born persons.
For both U.S.-born persons and non-U.S.–born persons in 2022, the percentage of cases was higher for male persons compared with female persons at every age group except ages 5–14 years.
Among persons aged 5–14 years, 53.4% of cases among non-U.S.–born persons and 54.3% of cases among U.S.-born persons occurred among female persons.
Learn more in the Executive Commentary.Data Tables
Open All Close AllOrigin of BirthTB by Origin of Birth: 1993–2022
TB by Origin of Birth, Sex, and Age Group: 2022
TB in the Top 30 Countries of Birth: 2018–2022
TB by Years in the United States: 1993–2022
TB by Origin of Birth and Reporting Area: 2022Race/EthnicityTB by Race/Ethnicity: 1993–2022
TB by Race/Ethnicity Among U.S.-Born Persons: 1993–2022
TB by Race/Ethnicity Among Non-U.S.–Born Persons: 1993–2022AgeTB by Age Group: 1993–2022
TB by Age Group Among U.S.-Born Persons: 1993–2022
TB by Age Group Among Non-U.S.–Born Persons: 1993–2022
TB by Age Group and Reporting Area: 2022
TB by Origin of Birth, Sex, and Age Group: 2022SexTB by Origin of Birth, Sex, and Age Group: 2022Top of Page
							
					
							Last Reviewed:  November 15, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue